Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Bullboard Posts
Comment by LaserStock29on Aug 01, 2020 3:44pm
207 Views
Post# 31354213

RE:RE:RE:RE:RE:RE:Theralase = TLD-1433

RE:RE:RE:RE:RE:RE:Theralase = TLD-1433
Eoganacht wrote: So thadeush - you think Dr. Kulkarni and/or Dr. Kassouf were bribed by "big pharma" to sabotage the treatment of the critically ill cancer patients in their care. And then the ever-obliging Theralase covered for them by publicly stating that the problem was not with those running the trial but with the clinical protocol that was submitted to them by the company. I guess big pharma also bribed Theralase to sabotage their own trial.
thadeush wrote: I know they're probably monitoring the testing meticulously and I hate to bring this up, but the conspiracy part of my personality thinks that the success of TLT's Phase 2 might bring quite a bit of pain to the stock price of other treatments. Is it possible that any of the doctors doing the test could have been 'incentivised' by some large pharma groups to alter the doses and throw off the results? I doubt they'd be able to get away with altering the likely much more closely watched second treatment, but things are pretty ruthless when this kind of money is involved. I only bring it up because the results seem like such an anamoly.




Consider all the dosimitry work done by Dr.Lilge et al... eliminating meticiously one objection at a time... the ability to measure light.. incidence and refractory.... 'bouncing off the luminal layer'  automatically calculated by a computer...  Monte Carlo then the upgraded Full Monte. etc


Then consider 2016 AGM   9:40

2016 Agm


Then consider 2016 AGM mark

2016 AGM Dosimitry Avoiding Overtreatment and Undertreatment 13:47


Im sure science is difficult and once you get to actually do things in life... sure a curveball here or there can happen.. But im sorry... There was 1 month between patients one and two (March 3 and April 7) for which we were told via NR.

Are we to believe that Dr.Lilge wasn't emailed, cc'd or forwarded the dosimitry......
"Hi Dr.Lilge, here is the data from the first patient, can you check and confirm that the dose is accurate to the projected modelling of patients bladder by the computer system.. is this patients bladder sufficiently 'treated'   and not over/under treated.

This inter-phase 1 review was done and we experienced a 6 month delay between patients while we 'Optimized' the treatment further.....  so why wasn't that same consideration done for Phase 2?   Again considering so much time was between patients.   It's not like we rattled off 10 in a week and could say whoops...... look at that... no time to make an adjustment.

Man oh man........ I try to be as rational about these things..... and not conspiracy oriented..... but I dont like the incomplete report we were given..




Lets put it this way just read what was the Late 80's and Early 90's on Photofrin.. the numbers around this..

1993 Trial Photofrin Japan


2004 Quebec Review of PDC PDT


Then consider Dr.Wilson

Photodynamic Therapy Review 2011


In my mind it's not possible to have results like this worse than photofrin......  it seems fishy as fuc*
Bullboard Posts